Dacliximab

Dacliximab is a monoclonal antibody that is used in the treatment of multiple sclerosis. It is a humanized IgG1 monoclonal antibody that binds to CD25, a receptor subunit that is expressed on the surface of T lymphocytes.

Mechanism of Action

Dacliximab works by binding to the alpha subunit (CD25) of the high-affinity interleukin-2 receptor on T cells. This binding inhibits the activation of T cells, which are known to play a role in the pathogenesis of multiple sclerosis.

Clinical Use

Dacliximab is used in the treatment of relapsing forms of multiple sclerosis. It is administered as a subcutaneous injection once a month.

Side Effects

The most common side effects of dacliximab include rash, lymphadenopathy, and nausea. Serious side effects can include liver damage, immune disorders, and infections.

Contraindications

Dacliximab is contraindicated in patients with a known hypersensitivity to dacliximab or any of its components. It is also contraindicated in patients with severe liver impairment.

Drug Interactions

Dacliximab may interact with other drugs that affect the immune system, such as corticosteroids and immunosuppressants.

See Also

• Monoclonal antibodies
• Multiple sclerosis
• CD25
• Interleukin-2 receptor

Dacliximab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski